Vue transversale de la maladie
Myopathies
Un même point d’entrée pour les études cliniques, les découvertes scientifiques, les publications et les pistes exploratoires présentes dans Biomedical Watch.
Périmètre
Filtrer toute la vue
Chaque choix s’applique immédiatement aux quatre sections. Le filtre « type de SEP » n’apparaît que lorsque la sclérose en plaques est sélectionnée.
1012 résultats correspondants
· 46 visibles sur cette page
dans le périmètre Myopathies
Niveau clinique
Études et traitements 421
Interventions, programmes et essais cliniques rattachés au périmètre sélectionné.
| Molécule / élément | Maladie / population | Objectif | Phase / stade | Statut / preuve | Mécanisme / résumé | Source | Détail |
|---|---|---|---|---|---|---|---|
| Abdominal and Core Exercises on Respiratory Functions in Obese and Ov… NCT07103499 · NCT07103499 | Myopathies | À vérifier | Non applicable | COMPLETED | This study aims to examine the effects of an 8-week Pilates-based exercise… À vérifier | ClinicalTrials.gov 2026-09-14 15:37:00 | Détail |
| Da-Cheng-Qi Decoction Plus Standard Western Treatment NCT07816900 · Efficacy and Safety of Da-Cheng-Qi Decoction in Severe Acute Pancreatitis | Myopathies | Traitement symptomatique | Non applicable | COMPLETED | This single-center prospective randomized controlled trial evaluated Da-Ch… À vérifier | ClinicalTrials.gov 2026-09-14 15:37:00 | Détail |
| Data Collection of Standard Care of Patients in the EMG Section NCT05041387 · NCT05041387 | Myopathies | Traitement symptomatique · Thérapie génique | À vérifier | RECRUITING | Background: Most people who are referred to the EMG (Electromyography) Sec… À vérifier | ClinicalTrials.gov 2026-09-14 15:37:00 | Détail |
| Effects of Dry Needling on Electromyographic Activity and Ultrasonogr… NCT06017960 · NCT06017960 | Myopathies | Ralentissement de la progression · Traitement symptomatique · Thérapie génique | Non applicable | COMPLETED | Stroke is a global health problem, with an incidence in Europe of 147/100,… À vérifier | ClinicalTrials.gov 2026-09-14 15:37:00 | Détail |
| EXOPULSE Mollii Suit and EXOPULSE Suit NCT05901259 · EXOREG — The EXOPULSE Study - a Database for Routine Follow-up of Clinical Outco… | Myopathies | Traitement symptomatique | À vérifier | RECRUITING | The objective is to explore the potential short and long-term impact of th… À vérifier | ClinicalTrials.gov 2026-09-14 15:37:00 | Détail |
| FAST for DM - Fatty Acid Supplementation Trial (FAST) for Dermatomyos… NCT07111065 · NCT07111065 | Myopathies | Traitement symptomatique | Phase 2 | RECRUITING | Dermatomyositis (DM) is a rare autoimmune disease that causes muscle weakn… À vérifier | ClinicalTrials.gov 2026-09-14 15:37:00 | Détail |
| Fibromyalgia-Related Quality of Life and Exercise Motivation NCT07777393 · NCT07777393 | Myopathies | À vérifier | À vérifier | COMPLETED | The objective of this study is to evaluate possible correlations between m… À vérifier | ClinicalTrials.gov 2026-09-14 15:37:00 | Détail |
| low-calorie low-protein NCT03573739 · NUTRIREA3 — Impact of Early Low-Calorie Low-Protein Versus Standard Feeding on O… | Myopathies | Thérapie génique | Non applicable | COMPLETED | Among critically ill patients requiring mechanical ventilation and catecho… À vérifier | ClinicalTrials.gov 2026-09-14 15:37:00 | Détail |
| Outcomes of Neurosurgical Tone Management NCT07817745 · NCT07817745 | Myopathies | Traitement symptomatique · Thérapie génique | À vérifier | RECRUITING | Patients with spastic/dystonic quadriplegia (GMFCS IV/V) are often severel… À vérifier | ClinicalTrials.gov 2026-09-14 15:37:00 | Détail |
| PF-08154225 NCT07782450 · A Study to Learn About a Medicine Called PF-08154225 in Participants With Autoim… | Myopathies | Immunomodulation · Thérapie génique | Phase 1/2 | NOT_YET_RECRUITING | The purpose of this study is to learn about the safety and effects of the… À vérifier | ClinicalTrials.gov 2026-09-14 15:37:00 | Détail |
| R01_Pilot Jaw Muscle Phenotypes NCT07153107 · NCT07153107 | Myopathies | Traitement symptomatique | Non applicable | NOT_YET_RECRUITING | The proposed study will assess the effect of local heat therapy on jaw pai… À vérifier | ClinicalTrials.gov 2026-09-14 15:37:00 | Détail |
| synovial biopsy NCT07503821 · SYVIPRO — Synovial Tissue as a Biomarker in the Management of Pigmented Villonod… | Myopathies | Immunomodulation · Traitement symptomatique | Non applicable | RECRUITING | Pigmented villonodular synovitis (PVNS) is a rare joint disease caused by… À vérifier | ClinicalTrials.gov 2026-09-14 15:37:00 | Détail |
| transcutaneous vagus nerve stimulation NCT06009159 · Vagus Nerve Stimulation(VNS) As Treatment For Fibromyalgia Patients | Myopathies | À vérifier | Non applicable | RECRUITING | Attaining goals or rewards commonly entails response costs. In light of co… À vérifier | ClinicalTrials.gov 2026-09-14 15:37:00 | Détail |
| Yangyin Roujin Decoction NCT07736144 · Mechanism Study of Yangyin Roujin Formula in the Treatment of Fibromyalgia Syndr… | Myopathies | Traitement symptomatique | Non applicable | RECRUITING | This prospective randomized, double-blind, controlled clinical trial is de… À vérifier | ClinicalTrials.gov 2026-09-14 15:37:00 | Détail |
| ABLE Kids NCT07745712 · Clinical Investigation to Validate the Safety and Performance of the ABLE Kids D… | Myopathies | À vérifier | Non applicable | RECRUITING | The primary objective of the study is to validate the safety and clinical… À vérifier | ClinicalTrials.gov 2026-09-14 12:37:06 | Détail |
| Active Coping: Interdisciplinary Program for Chronic Pain, Physiother… NCT07504094 · NCT07504094 | Myopathies | Traitement symptomatique | Non applicable | ACTIVE_NOT_RECRUITING | The goal of this observational intervention study is to evaluate the impac… À vérifier | ClinicalTrials.gov 2026-09-14 12:37:06 | Détail |
| AXS-14 (esreboxetine) NCT07637162 · Open-Label Safety Study of AXS-14 in Subjects With Fibromyalgia | Myopathies | À vérifier | Phase 3 | ENROLLING_BY_INVITATION | This is a Phase 3, multi-center, 52-week, open-label trial to evaluate the… À vérifier | ClinicalTrials.gov 2026-09-14 12:37:06 | Détail |
| AXS-14 (esreboxetine) NCT07398417 · FORWARD — Fibromyalgia Response With Esreboxetine Evaluated Using a Randomized W… | Myopathies | À vérifier | Phase 3 | RECRUITING | This is a Phase 3, multi-center, 52-week, open-label trial to evaluate the… À vérifier | ClinicalTrials.gov 2026-09-14 12:37:06 | Détail |
| BMS-986368 NCT06782490 · MSS — A Study to Evaluate the Efficacy, Safety and Tolerability of BMS-986368 in… | Myopathies | Traitement symptomatique | Phase 2 | RECRUITING | This is a study to evaluate the efficacy, safety, and tolerability of BMS-… À vérifier | ClinicalTrials.gov 2026-09-14 12:37:06 | Détail |
| Craniovertebral Angle and Fibromyalgia Severity NCT06957873 · NCT06957873 | Myopathies | Traitement symptomatique | À vérifier | RECRUITING | Forward Head Posture Frequency in Fibromyalgia Patients Assessed by Cranio… À vérifier | ClinicalTrials.gov 2026-09-14 12:37:06 | Détail |
Découverte scientifique
Recherches et trouvailles 0
Projets précliniques, publications émergentes et programmes de recherche suivis dans le pipeline.
| Molécule / élément | Maladie / population | Objectif | Phase / stade | Statut / preuve | Mécanisme / résumé | Source | Détail |
|---|---|---|---|---|---|---|---|
| Aucune trouvaille ne correspond aux filtres. | |||||||
Bibliographie
Publications 585
Références bibliographiques de la base locale et accès à leur source originale.
| Molécule / élément | Maladie / population | Objectif | Phase / stade | Statut / preuve | Mécanisme / résumé | Source | Détail |
|---|---|---|---|---|---|---|---|
| Vagus nerve stimulation as an add-on therapy in patients with epileps… Vagus nerve stimulation · PMID 42581390 | Myopathies | À vérifier | Publication | PubMed | Voir la publication source Vagus nerve stimulation (VNS) has been proven as an effective and safe adjunct therapy for epilepsy, but real-world evi… | Acta epileptologica 2026-08-13 15:03:55 | Source |
| Vamorolone for Duchenne Muscular Dystrophy: A Cross-Trial Efficacy Co… Vamorolone · PMID 42531535 | Myopathies | À vérifier | Publication | PubMed | Voir la publication source Résumé non disponible dans la base locale. | Neurology 2026-08-13 15:03:55 | Source |
| Remogliflozin Attenuates Thioacetamide-Induced Nephrotoxicity: Associ… SGLT2 inhibitor · PMID 42590936 | Myopathies | Neuroprotection · Immunomodulation | Publication | PubMed | Voir la publication source Thioacetamide (TAA) induces renal injury via oxidative stress and inflammation. Remogliflozin (Remo), an SGLT2 inhibito… | Toxicology mechanisms and methods 2026-08-13 15:03:54 | Source |
| SGLT2 Inhibitors and Outcomes in Elderly Patients With Chronic Kidney… SGLT2 inhibitor · PMID 42587349 | Myopathies | À vérifier | Publication | PubMed | Voir la publication source Sodium-glucose cotransporter 2 (SGLT2) inhibitors have emerged as a cornerstone therapy for chronic kidney disease (CKD… | Diabetes, obesity & metabolism 2026-08-13 15:03:54 | Source |
| Kidney outcomes and safety of sodium-glucose cotransporter-2 inhibito… SGLT-2 inhibitor · PMID 42586506 | Myopathies | Thérapie génique | Publication | PubMed | Voir la publication source Autosomal dominant polycystic kidney disease (ADPKD) is the most common hereditary kidney disease and among the leading… | Diabetes research and clinical practice 2026-08-13 15:03:53 | Source |
| AAV-mediated gene transfer of a novel microdystrophin ameliorates pat… RGX-202 · PMID 42003884 | Myopathies | À vérifier | Publication | PubMed | Voir la publication source Use of adeno-associated virus (AAV)-mediated transfer of functional microdystrophins to address Duchenne muscular dystr… | Molecular therapy. Nucleic acids 2026-08-13 15:03:52 | Source |
| Targeting the creatine transporter SLC6A8: Mechanisms and emerging th… RGX-202 · PMID 42297217 | Myopathies | Remyélinisation indirecte / réparation · Thérapie génique | Publication | PubMed | Voir la publication source Solute carrier family 6 member 8 (SLC6A8) is a Na- and Cl-dependent creatine transporter that mediates the transmembran… | Biochemical pharmacology 2026-08-13 15:03:52 | Source |
| AAV microdystrophin gene replacement therapy for Duchenne muscular dy… PF-06939926 · PMID 40817386 | Myopathies | Thérapie cellulaire · Thérapie génique | Publication | PubMed | Voir la publication source Duchenne muscular dystrophy (DMD) is caused by pathogenic sequence variants occurring in the DMD gene which lead to the… | Gene therapy 2026-08-13 15:03:50 | Source |
| Cardiac safety of fordadistrogene movaparvovec gene therapy in Duchen… PF-06939926 · PMID 40583273 | Myopathies | Ralentissement de la progression · Thérapie génique | Publication | PubMed | Voir la publication source Fordadistrogene movaparvovec (FM; PF-06939926) is a recombinant adeno-associated virus serotype-9 gene-replacement cons… | Molecular therapy : the journal of the American Societ… 2026-08-13 15:03:50 | Source |
| An Antibody-Oligonucleotide Conjugate for Myotonic Dystrophy Type 1. Del-desiran (AOC 1001) · PMID 41707138 | Myopathies | Thérapie génique | Publication | PubMed | Voir la publication source Myotonic dystrophy type 1 is a rare, dominantly inherited, progressive, disabling, neuromuscular disease that leads to… | The New England journal of medicine 2026-08-13 15:03:49 | Source |
| Effect of using knee extension aid for gait training in subacute hemi… Extension assist knee ankle foot orthosis (EA-KAFO) · PMID 42544336 | Myopathies | À vérifier | Publication | PubMed | Voir la publication source [Purpose] In normal gait, the knee flexes approximately 60° during the swing phase, and the lower leg's inertial force… | Journal of physical therapy science 2026-08-13 15:03:49 | Source |
| Robot-Assisted Gait Training to Improve Gait Patterns in Two Adolesce… Extension assist knee ankle foot orthosis (EA-KAFO) · PMID 41332284 | Myopathies | À vérifier | Publication | PubMed | Voir la publication source Although the effectiveness of robot-assisted gait training (RAGT) in stroke has been reported, evidence in adolescents… | Physical & occupational therapy in pediatrics 2026-08-13 15:03:49 | Source |
| BMN 351-Induced Exon Skipping and Dystrophin Expression in Skeletal a… BMN 351 · PMID 39916519 | Myopathies | Thérapie génique | Publication | PubMed | Voir la publication source Duchenne muscular dystrophy (DMD) is caused by mutations of the gene that prevent the expression of functional dystroph… | Nucleic acid therapeutics 2026-08-13 15:03:48 | Source |
| Targeting a Novel Site in Exon 51 with Antisense Oligonucleotides Ind… BMN 351 · PMID 39916530 | Myopathies | Thérapie génique | Publication | PubMed | Voir la publication source Exon skipping with antisense oligonucleotides (ASOs) can correct disease-causing mutations of Duchenne muscular dystrop… | Nucleic acid therapeutics 2026-08-13 15:03:48 | Source |
| From design to clinic: Medicinal chemistry and pharmacology of approv… Givinostat · PMID 42546588 | Myopathies | À vérifier | Publication | PubMed | Voir la publication source Many diseases, including cancer, are characterized by increased or decreased expression of specific genes. These change… | European journal of medicinal chemistry 2026-08-13 15:03:47 | Source |
| Real-world safety profile of givinostat: an early post-marketing phar… Givinostat · PMID 42494524 | Myopathies | Ralentissement de la progression | Publication | PubMed | Voir la publication source Givinostat is a novel histone deacetylase inhibitor, which was approved by the US Food and Drug Administration (FDA) in… | Frontiers in pharmacology 2026-08-13 15:03:47 | Source |
| Bone marrow mesenchymal stem cell exosomes in osteonecrosis: patholog… Human Umbilical Cord Mesenchymal Stem Cells (UC-MSC) · PMID 42550377 | Myopathies | Traitement symptomatique · Thérapie cellulaire | Publication | PubMed | Voir la publication source Osteonecrosis is bone death caused by disrupted blood supply. It often leads to bone collapse and joint failure. Curren… | Molecular biology reports 2026-08-13 15:03:46 | Source |
| Subconjunctival Injection of Mesenchymal Stem Cells for Corneal Wound… Human Umbilical Cord Mesenchymal Stem Cells (UC-MSC) · PMID 42454124 | Myopathies | Immunomodulation · Thérapie cellulaire | Publication | PubMed | Voir la publication source Previous studies in animal models have demonstrated that mesenchymal stem cells (MSCs) are beneficial for reconstructin… | Frontiers in medicine 2026-08-13 15:03:46 | Source |
| Development of a DUX4-targeting antibody oligonucleotide conjugate as… AOC-1020 · PMID 41994867 | Myopathies | Thérapie génique | Publication | PubMed | Voir la publication source Facioscapulohumeral muscular dystrophy (FSHD) is an autosomal dominant muscular disease in which genetic mutations acti… | Nucleic acids research 2026-08-13 15:03:45 | Source |
| Preclinical evaluation of INS1201 AAV9-micro-dystrophin via CSF admin… INS1201 · PMID 42137291 | Myopathies | Immunomodulation | Publication | PubMed | Voir la publication source INS1201 is an investigational adeno-associated virus 9-micro-dystrophin gene transfer therapy under development as a po… | Molecular therapy. Advances 2026-08-13 15:03:44 | Source |
Exploration — prudence
Pistes exploratoires 6
Rapprochements mécanistiques et hypothèses de recherche : ils ne constituent pas une preuve d’efficacité ni une recommandation thérapeutique.
Hypothèses non validéesÀ confirmer par des travaux précliniques, cliniques et une revue scientifique indépendante.
| Molécule / élément | Maladie / population | Objectif | Phase / stade | Statut / preuve | Mécanisme / résumé | Source | Détail |
|---|---|---|---|---|---|---|---|
| N-PPG N-PPG — modulation métabolique cérébrale | Myopathies | Remyélinisation indirecte / réparation · Neuroprotection | Hypothèse exploratoire | Rapprochement automatique non validé | Modulation métabolique et mitohormèse N-PPG est étudié dans Maladie de Huntington et documente plusieurs axes biologiques pouvant être pertinents pour Myopat… | Rapprochement Biomedical Watch · Maladie de Huntington | Détail |
| Vecteur Ple389 (ADORA2A) MiniPromoter Ple389 — ciblage striatal | Myopathies | Thérapie génique | Hypothèse exploratoire | Rapprochement automatique non validé | Expression génique ciblée dans les neurones striataux Vecteur Ple389 (ADORA2A) est étudié dans Maladie de Huntington et documente plusieurs axes biologiques pouvant être per… | Rapprochement Biomedical Watch · Maladie de Huntington | Détail |
| α-Amyrin α-Amyrin — protection mitochondriale | Myopathies | Remyélinisation indirecte / réparation · Neuroprotection | Hypothèse exploratoire | Rapprochement automatique non validé | Protection mitochondriale et modulation de la pathologie Tau α-Amyrin est étudié dans Maladie d’Alzheimer et documente plusieurs axes biologiques pouvant être pertinents pour Myopa… | Rapprochement Biomedical Watch · Maladie d’Alzheimer | Détail |
| 4-octyl itaconate et dérivés Dérivés de l’itaconate — neuroinflammation | Myopathies | Neuroprotection · Immunomodulation | Hypothèse exploratoire | Rapprochement automatique non validé | Modulation immunométabolique de la microglie 4-octyl itaconate et dérivés est étudié dans Sclérose latérale amyotrophique et documente plusieurs axes biologiques po… | Rapprochement Biomedical Watch · Sclérose latérale amy… | Détail |
| Thonningianin A Thonningianin A — neuroprotection anti-amyloïde | Myopathies | Neuroprotection | Hypothèse exploratoire | Rapprochement automatique non validé | Modulation du stress oxydatif et des protéines associées à Alzheimer Thonningianin A est étudié dans Maladie d’Alzheimer et documente plusieurs axes biologiques pouvant être pertinents pou… | Rapprochement Biomedical Watch · Maladie d’Alzheimer | Détail |
| Vutiglabridin Vutiglabridin — autophagie et PON2 | Myopathies | Neuroprotection | Hypothèse exploratoire | Rapprochement automatique non validé | Activation de PON2 et stimulation de l’autophagie Vutiglabridin est étudié dans Maladie d’Alzheimer et documente plusieurs axes biologiques pouvant être pertinents pour… | Rapprochement Biomedical Watch · Maladie d’Alzheimer | Détail |